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Abstract
The SalI-L fragment from human herpesvirus 6A (HHV-6A) encodes a protein DR7 that has been reported to produce
fibrosarcomas when injected into nude mice, to transform NIH3T3 cells, and to interact with and inhibit the function of p53.
The homologous gene in HHV-6B is dr6. Since p53 is deregulated in both HHV-6A and -6B, we characterized the expression
of dr6 mRNA and the localization of the translated protein during HHV-6B infection of HCT116 cells. Expression of mRNA
from dr6 was inhibited by cycloheximide and partly by phosphonoacetic acid, a known characteristic of herpesvirus early/
late genes. DR6 could be detected as a nuclear protein at 24 hpi and accumulated to high levels at 48 and 72 hpi. DR6
located in dots resembling viral replication compartments. Furthermore, a novel interaction between DR6 and the viral DNA
processivity factor, p41, could be detected by confocal microscopy and by co-immunoprecipitation analysis. In contrast,
DR6 and p53 were found at distinct subcellular locations. Together, our data imply a novel function of DR6 during HHV-6B
replication.
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Introduction
Human herpesvirus (HHV)-6 comprises two genetically closely
related variants named A and B. Despite their relatedness, HHV-
6A and -6B display distinct epidemiologic and biologic character-
istics, including their disease spectrum, suggesting that they are
distinct species [1]. At the age of two, most individuals in the
western world have been infected with HHV-6B [2,3], which
causes the childhood disease exanthem subitum [4]. The
epidemiology of HHV-6A is less well known. Whereas HHV-6A
is believed to be more neurotropic [5,6], HHV-6B is frequently
associated with salivary glands and may be the only HHV-6
variant associated with saliva [7]. The molecular basis for the
epidemiological and biological differences between HHV-6A and -
6B is poorly understood. Although both viruses have 9 variant-
specific open reading frames (ORFs) [8,9], it remains to be
demonstrated whether or not they encode functional proteins.
Previously, we and others have reported that regulation of p53 is
disturbed in HHV-6A and -6B-infected cells [10,11,12]. Major
cellular pathways, including apoptosis and cell cycle arrest, are
regulated by p53, and consequently, mutations in p53 are a
frequent finding in many forms of cancer [13]. The protein
product of orf-1 (here termed ORF-1(6A)) identified in the SalI-L
fragment of HHV-6A (U1102) [14] has been reported to bind p53
[15]. Using various truncated constructs of p53, ORF-1(6A)
binding was mapped to a region within residues 28 to 187, which
includes the C-terminal half of the p53 transcriptional activation
domain and the N-terminal half of the DNA-binding domain.
Cells expressing ORF-1(6A) were inhibited in p53-activated
transcription, and ORF-1(6A) was able to transform NIH3T3
cells in vitro and to induce fibrosarcomas in vivo when injected into
nude mice [15]. This viral protein was predicted to be 357 amino
acids [16], and has been suggested to correspond to the protein
product of direct repeat 7 (DR7) [9], here designated DR7(6A),
although the nucleotide sequence for dr7(6A) encodes a predicted
protein of 363 amino acids. In addition to this unspliced product, a
spliced product is predicted to originate from dr6 in both HHV-6A
(395 amino acids), here designated dr6(6A), and HHV-6B (392
amino acids), designated dr6(6B).
Based on the transforming and trans-activating abilities of ORF-
1(6A), DR6(6B) has also been proposed to be a trans-activator. To
understand further the function of DR6(6B) in HHV-6B-infected
cells, we have generated a polyclonal anti-DR6 antibody.
Characterization of DR6(6B) expression and localization during
infection suggests novel functions for this viral protein.
Results
Nucleotide alignments of the HHV-6A/B genomes
encoding ORF-1(6A), DR7(6A), DR6(6A), and DR6(6B)
According to the HHV-6A nucleotide sequence (NC_001664),
DR6(6A) and DR7(6A) is encoded from a region between nt 4725
and 6720 (Figure 1A). The SalI-L fragment (nt 4728 to 8654)
includes this region with the exception of the ATG that is
necessary for translation of the dr6(6A) coding sequence
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7457(Figure 1A). Therefore, the orf-1(6A) may encode DR7(6A),
although it is not known whether this protein product is generated
during HHV-6A infection.
In the HHV-6B genome (NC_000898), the nt 5027 – 5330 is
joined to 6329 – 7203 to generate the coding sequence for
DR6(6B) (Figure 1B). Similarity between orf-1(6A), dr6(6A),a n d
dr7(6A) was expected, but surprisingly the 39-end of the orf-1(6A)
is almost identical to dr6(6B),b u tn o tt odr6(6A) or dr7(6A).
Inspection of the sequences reveal that dr6(6A) and consequently
dr7(6A) have a sequence that reads AGTGG as opposed to
AGGTGGG in orf-1(6A) and CAGTCGG dr6(6B) (Figure 1C).
Thus, the lack of a G before and after T alters the reading frame
and results in the prediction of a different protein (Figure 1C and
1D). Insertion of G’s in position 6664 and 6666 of dr6(6A) and
dr7(6A) would maintain a reading frame comparable to orf-1(6A)
and dr6(6B) and introduce an earlier stop codon. This could
explain the inconsistency in length of the predicted proteins from
orf-1(6A) (357 amino acids) and dr7(6A) (363 amino acids).
Moreover, this insertion of G’s would result in nearly identical
coding sequences for dr6(6A) and dr6(6B). We propose that the
multiple G’s in the sequence AGGTGGG could have led to a
misreading of the sequence (AGTGG) for dr6(6A) and dr7(6A),
and suggest therefore that DR6(6A) and DR6(6B) are more
similar than initially predicted and may serve the same
functions.
Expression of dr6(6B) mRNA and protein in HHV-6B-
infected cells
To examine whether dr6 mRNA was expressed during HHV-6B
infection, we used real-time PCR. Expression of dr6(6B) mRNA
was significant at 24 hours post infection (hpi) in both HCT116
and MOLT3 cells (Figure 2A–D). The presence of inhibitors of
early (cycloheximide, CHX) and late (phosphonoacetic acid, PAA)
genes, indicated that the dr6(6B) gene followed an expression
pattern characteristic of an early/late gene, as it was inhibited by
the presence of CHX (Figure 2A and 2C), and the presence of
Figure 1. Alignments of dr7(6A), dr6(6A), orf-1(6A), and dr6(6B). (A) Schematic alignment of the dr6 gene from HHV-6A (NC_001664, nt 4725-
6720) with the SalI-L fragment (X73675), the orf-1 from the SalI-L fragment [14], the dr6(6A) and dr7(6A) open reading frame [9]. (B) Schematic
alignment of dr6 gene of HHV-6B (NC_000898, nt 5027-7203). Arrows indicate the primers used for amplification by real-time PCR. (C) Alignment of
the 39-end of dr7(6A), dr6(6A), orf-1(6A), and dr6(6B). Nt 6664 indicates the position where a frameshift takes place in dr6(6A) and dr7(6A). (D)
Alignment of the C-terminal tail of DR7(6A), DR6(6A), ORF-1, and DR6(6B). The amino acid sequence for the antigenic peptide is indicated.
doi:10.1371/journal.pone.0007457.g001
DR6-p41 Complex Formation
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kinetics of expression was similar in HCT116 and MOLT3 cells.
To demonstrate that the presence of dr6(6B) mRNA resulted in
translation to a viral protein, a polyclonal rabbit anti-DR6
antibody against the C-terminal fragment of DR6(6B) was used
(Figure 1D). In HHV-6B-infected cells, this antibody recognized a
protein of an apparent MW of 44 kDa that was not recognized in
the presence of the blocking peptide against which the antibody
was raised (Figure 2E). Using this antibody, the expression of
DR6(6B) in HHV-6B-infected HCT116 cells was clearly detect-
able at 24 hpi, and the expression increased dramatically at 48 and
72 hpi (Figure 2F). This indicated that high levels of DR6(6B) were
expressed during HHV-6B infection.
Different localization of DR6 and p53 in HHV-6B-infected
cells
In HHV-6A-infected cells, DR7(6A) has been proposed to
bind p53 and inhibit its transcriptional activity. Since p53
transcriptional activity also appears to be inhibited in HHV-6B-
infected cells, we examined whether DR6(6B) co-localized with
p53 in HHV-6B-infected HCT116 cells. To verify that our anti-
DR6 antibody did not give rise to non-specific signals on
confocal microscopy, we first examined the expression of
DR6(6B) at 24 hpi in the presence or absence of the blocking
peptide against which the antibody was raised. This indicated
that our anti-DR6 antibody did not bind non-specifically
through sites other than the antigen-specific site (Figure 3A).
Confocal microscopy identified DR6(6B) at 24 and 48 hpi
(Figure 3A and B), consistent with the Western blotting analysis
(Figure 2F). Whereas DR6(6B) was located in the nucleus, the
distribution of p53 was almost exclusively cytoplasmic in
H C T 1 1 6c e l l st h a tw e r eH H V - 6 Bi n f e c t e d ,a sj u d g e db y
expression of p41 (Figure 3C). As expected, uninfected
HCT116 cells expressed undetectable levels of p53. This
demonstrated that DR6(6B) and p53 localize to different cellular
compartments during HHV-6B infection.
Figure 2. Expression of dr6 mRNA and protein in HHV-6B-
infected cells. (A–D) Relative expression of dr6 mRNA using tbp mRNA
as reference. HCT116 (A and B) or MOLT3 (C and D) cells were incubated
in the presence or absence of CHX (A and C) or PAA (B and D) and lysed
at the indicated timepoint followed by mRNA extraction. (E) Anti-DR6
polyclonal antibodies identified a 44 kDa band by Western blotting,
which was blocked by the addition of a DR6(6B) peptide. The peptide
sequence was as shown in Figure 1D. (F) Western blotting of HCT116
cell extract at 24, 48, and 72 hpi. Expression of DR6(6B) and GAPDH is
shown. A representative of 3 experiments is shown.
doi:10.1371/journal.pone.0007457.g002
Figure 3. Separate localization of DR6(6B) and p53 in HHV-6B-
infected cells. (A) Confocal laser scanning microscopy of DR6(6B)
(green) at 24 hpi in the presence or absence of a DR6(6B) blocking
peptide. The peptide sequence is shown in Figure 1D. DNA was stained
with DAPI (blue). Multiple cells forming a characteristic ring structure
are shown. (B) Distribution of DR6(6B) (green) at 48 hpi. A
representative cell is shown. (C) Distribution of p53 (red) and p41
(green) at 48 hpi. The size of the cells in (A), (B) and (C) are similar, but
(B) is shown at 3x higher magnification than are (A) and (C). A
representative of three experiments is shown.
doi:10.1371/journal.pone.0007457.g003
DR6-p41 Complex Formation
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distribution of TBP
The distribution of DR6(6B) observed by confocal microscopy
suggested that it was almost exclusively nuclear. To further
demonstrate this, we separated nuclear and cytoplasmic fractions
from HHV-6B-infected HCT116 cells at 48 hpi. This indicated that
the vast majority of DR6(6B) was found in the nuclear fraction with
barely detectable levels in the cytoplasmic fraction (Figure 4A).
Controls indicated that the cytoplasmic fractions were pure, since
we were unable to detect the nuclear protein RCC1, whereas there
was some cytoplasmic contamination in the nuclear fractions, as
seen by the presence of GAPDH. This does not affect our
conclusion that DR6(6B) was almost exclusively found in the
nucleus during HHV-6B infection of HCT116 cells at 48 hpi.
To determine the distribution of DR6(6B) during the infection,
HHV-6B-infected HCT116 cells were examined at 24, 48, and 72
hpi. At the earliest timepoint examined, DR6(6B) appeared in the
nucleus and increased its intensity significantly at 48 and 72 hpi.
The staining pattern were reminiscent of a pattern seen in HSV-1-
infected cells by TATA binding protein (TBP) [17], a transcription
factor that is part of the RNA polymerase II preinitiation complex.
TATA box motifs may be present in promoters for a number of
viral genes. There was a high degree of co-localization between
DR6(6B) and TBP (Figure 4B), suggesting that these molecules
were functioning in the same nuclear compartment. When the
cells were infected by HHV-6B, an increased staining of TBP was
detected. The anti-TBP antibody detects an epitope that is
exposed when TBP binds DNA. Since TBP is not upregulated by
HHV-6B infection (data not shown), the most likely explanation of
the results is an increased binding of TBP to DNA during HHV-
6B infection.
Association of DR6 with the p41 viral DNA processivity
factor
The distribution pattern of DR6(6B) also resembles replication
compartments of viral DNA, as has been described for HSV-1
[18]. To pursue a potential role of DR6(6B) in viral DNA
replication, we examined the potential co-localization between
DR6(6B) and the viral DNA polymerase processivity factor p41.
Overall, DR6(6B) and p41 localized to the same compartments
within the nucleus of HHV-6B-infected HCT116 cells (Figure 5A).
Overlay analyses indicated that the majority of DR6(6B) co-
localized with p41, although p41 was more dominant at the border
of the nucleus. (Figures 5A and B). Software to calculate the co-
localization indicated that almost 90% of DR6(6B) co-localized
with p41, whereas only 40% of p41 co-localized with DR6(6B) at
48 hpi (Figure 5C).
Complex formation of DR6(6B) and p41 during HHV-6B
infection
Co-localization by confocal microscopy suggests that DR6(6B)
and p41 may have a functional relationship. To examine whether
these proteins physically associated in the same complex,
immunoprecipitates of p41 were probed for the presence of
DR6(6B). This demonstrated that DR6(6B) in the input lysate
(Figure 6A) co-immunoprecipitated with anti-p41, but not with
irrelevant IgG (Figure 6B). The post-immunoprecipitated lysate
indicated that a fraction of the DR6 was removed by anti-p41
when compared with irrelevant IgG (Figure 6C). Together, these
data indicated that DR6(6B) and p41 form a complex during
infection, either directly or indirectly.
Discussion
A major protein in controlling the antiviral response is p53, the
function of which is inhibited during HHV-6B infection. Early
experiments reported that the protein product from ORF-1 of the
SalI-L fragment of HHV-6A strain U1102 might bind to p53,
interfere with its transcriptional activity, leading to fibrosarcomas
in nude mice and transformation in NIH3T3 cell lines [15].
Consistent with the alignment shown in Figure 1, orf-1(6A) may
encode a protein from dr7(6A), since the SalI cleavage removes the
ATG from the dr6(6A) open reading frame. However, it has never
been shown that dr7(6A) encodes a protein during infections.
Based on these early studies, we speculated that DR6(6B) might
in part explain the altered p53 regulation in HHV-6B-infected
cells. To address this, we characterized the localization of DR6(6B)
during HHV-6B infection using the anti-DR6 antibody. Whereas
Figure 4. Nuclear distribution of DR6(6B) in a pattern similar to
TBP. (A) Separation of HCT116 lysate at 48 hpi into nuclear (NE) and
cytoplasmic (CY) fractions. Western blots were probed with anti-DR6,
anti-7C7 to indicate HHV-6B infection, anti-RCC1 as a nuclear protein
control, and anti-GAPDH as a cytoplasmic control. (B) Confocal laser
scanning microscopy of localization of DR6 and TBP at 24, 48, and 72
hpi. DNA was stained with DAPI. Columns with DR6/TBP and DNA/DR6/
TBP indicate an overlay of the individual stainings. A representative of
three experiments is shown.
doi:10.1371/journal.pone.0007457.g004
DR6-p41 Complex Formation
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7457the vast majority of p53 was located in the cytoplasm during
infection in HCT116 cells, DR6(6B) was almost exclusively
detected in the nucleus. Although remarkable, this dichotomy in
localization would not definitively rule out an association between
DR6(6B) and p53 in the nucleus. Nonetheless, based on the
distribution of p53 and DR6(6B) within the cellular compartments,
our data do not support the hypothesis that DR6(6B) acts as an
inhibitor of p53 during HHV-6B infection.
The above conclusion appears to be inconsistent with the results
from Kashanchi et al. [15]. The reason for this is not clear, but we
speculate that during ORF-1 overexpression, p53 and ORF-1 may
both localize to the nucleus. In contrast, during HHV-6B
infections, p53 is deregulated and the vast majority is located in
the cytoplasm, whereas DR6(6B) is found in the nucleus.
Moreover, the protein product of orf-1(6A) must be different from
the product of dr6(6B), since the ATG for dr6(6A) is cleaved by the
SalI enzyme and an alternative ATG is used for dr7(6A).
Confocal microscopy identified DR6(6B) in major nuclear dots
resembling replication compartments. These structures also con-
tained TBP and p41indicative of viral transcriptionand replication.
Importantly, p41 immunoprecipitation was able to co-precipitate
DR6(6B). This suggests that p41 and DR6(6B) are present within
the same complex involved in viral DNA replication. We do not
knowwhether p41 and DR6(6B) interacts physically, since DR6(6B)
may be co-precipitated via other proteins in the complex. Cloning
and expression of these proteins should illuminate potential
interactions between them in greater detail. Our confocal
microscopy studies have already demonstrated a high degree of
co-localization, although this was not complete. At least 10% of
DR6(6B) was located in the dots in the absence of p41 and almost
60% of p41 was located in the dots in the absence of DR6(6B). It is
unclear whether masking of antibody epitopes through protein-
protein or protein-DNA interactions may interfere with the
identification of the proteins and thus with these estimates, but we
cannot exclude the possibility that DR6(6B) is associated with
another protein in the complex.
DR6(6B) displayed a rapid nuclear translocation, although its
sequence has no known nuclear localization motif. This suggests
that DR6(6B) may use a novel motif or that it may be transported to
the nucleus by another protein, potentially a protein that directs
DR6(6B) to the replication compartments. After 48 to 72 hpi the
level of DR6(6B) increased steeply. Whether other viral proteins
produced before 24 hpi is important for the significant increase in
DR6(6B) levels or whether DR6(6B) via a positive feed-back loop
may transactivate itself remains to be defined. The latter possibility
would be consistent with a transactivating function of DR6(6B).
Either way it suggests the possibility that DR6(6B) is an important
protein for the further progression of the infection and is potentially
necessary for viral replication. We have attempted to knock-down
DR6(6B) protein levels using siRNA, but were unsuccessful in
eliminating DR6(6B) to an undetectable level judged by confocal
microscopy, even when specific siRNA was present before the
infection. To define definitively the role of DR6(6B) during HHV-
6B replication may therefore require a dr6(6B) mutant virus, which
is not available at the moment. In addition, although viral DNA
appears to be produced in HCT116 cells (data not shown), this cell
line is not thought to be productively infected, although this has not
been examined in detail.
Figure 5. Association of DR6(6B) and the p41 viral DNA processivity factor. (A) Confocal laser scanning microscopy of DR6(6B) (green) and
p41 (red) of HCT116 cells at 48 hpi. DNA was stained with DAPI (blue). Columns with DR6/p41 and DNA/DR6/p41 indicate an overlay of the individual
stainings. (B) High magnification of DR6/p41 overlay. (C) Co-localization coefficient computed by the LSM710 software. Ch1-DR6 indicates the fraction
of DR6(6B) that co-localized with p41. Ch2-p41 indicates the fraction of p41 that co-localized with DR6(6B). Values are the average of measurements
on 14 cells with an indication of standard deviation on top of the bars. A representative of three experiments is shown.
doi:10.1371/journal.pone.0007457.g005
DR6-p41 Complex Formation
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dr6 mRNA and the localization of the translated protein during
HHV-6B infection of HCT116 cells. We have further identified a
novel interaction between DR6(6B) and the viral DNA processivity
factor, p41, by confocal microscopy and by co-immunoprecipita-
tion analysis. In contrast, DR6 and p53 were found at distinct
subcellular locations. In addition to the previously reported
transactivating function on heterologous promoters, these studies
imply a novel function of DR6(6B) during viral DNA replication.
Materials and Methods
Cell lines and virus stock
The human epithelial colon carcinoma cell line HCT116 (a gift
from B. Vogelstein and K.W. Kinzler, Johns Hopkins University
School of Medicine, Baltimore, MD, USA), was grown in
McCoy’s medium (Gibco, California, USA), supplemented with
10% inactivated fetal calf serum (Sigma-Aldrich, Saint Louis,
USA), glutamine (0.2 g/L), HEPES (10 mM), penicillin (0.2 g/L),
streptomycin (0.2 g/L) (all from the Substrate Department,
Bartholin Building, Aarhus University, Denmark).
The immature T-cell line MOLT3 was grown in Isocoves
Modified Dulbecco Medium (IMDM) supplemented with 10%
inactivated fetal calf serum (Sigma), glutamine (0.2 g/L), HEPES
(10 mM), penicillin (0.2 g/L), streptomycin (0.2 g/L) (all from the
Substrate Department).
HHV-6B, strain PL1 (generated by Dr. P. Lusso, Milan, Italy),
was propagated in MOLT3 cells in IMDM supplemented with
10% inactivated fetal calf serum (Sigma), 0.5% nystatin (Gibco),
glutamine (0.2 g/L), HEPES (10 mM), penicillin (0.2 g/L),
streptomycin (0.2 g/L) (all from the Substrate Department). Virus
was collected from supernatants of HHV-6B infected MOLT3
cells by centrifugation at 3,200 xg for 1 hour to remove cell debris,
followed by a centrifugation at 25,000 xg at 4u C for 3 hours to
pellet virus particles. The virus particles were resuspended in
IMDM and the viral titer was determined in a Reed and Munch
assay to be 75 TCID50 [19]. Prior to each experiment including
HHV-6B infection, the virus stock was diluted 1:10.
Alignments
Using the BLOSUM62 alignment algorithm from CLCbio
workbench (Aarhus, Denmark) the nucleotide sequences from SalI-
L fragment of HHV-6A (X73675) [14], orf-1(6A) from SalI-L [14],
dr6(6A) and dr7(6A) (NC_001664) [9] were aligned against dr6(6B)
from HHV-6B (NC_000898)[8]. Furthermore, the predicted
protein sequences from DR7(6A), DR6(6A), ORF-1(6A), and
DR6(6B) were aligned.
RNA extraction
HCT116 cells (5610
5) were infected with HHV-6B diluted 1:15
in McCoy’s medium. RNA was isolated at 6, 24 and 48 hpi. An
equal amount of infected cells were treated with either 50 mg/ml
CHX (Sigma-Aldrich, Vallensbæk Strand, Denmark) or 200 mg/ml
PAA (Sigma-Aldrich) at 6, 24, and 48 hpi. For RNA isolation, the
cells were washedinphosphate-buffered saline(PBS) and totalRNA
was isolated at RT using a High Pure RNA Isolation kit (Roche
Diagnostics Scandinavia AB, Hvidovre, Denmark) as described
previously [20]. RNA was eluted in nuclease-free, sterile, double-
distilled H2O in a total volume of 50 ml. Total RNA concentrations
were determined by absorbance measurements using a NanoDrop
1000 instrument (Thermo Scientific, Wilmington, DE, USA).
cDNA synthesis and real-time PCR
Purified RNA was briefly incubated in gDNA Wipeout Buffer
(Quantitect Reverse Transcriptase kit, Qiagen, Copenhagen,
Denmark) at 42uC for 2 minutes to remove contaminating
genomic DNA. Subsequently, cDNA was synthesized from 0.5–
1 mg RNA using Quantitect Reverse Transcriptase kit. Amplifi-
cation of cDNA was performed in duplicate by real-time PCR on a
LightCycler instrument (Roche Diagnostics) in the presence of 2 ml
cDNA, 3.5 mM MgCl2, 0.5 mM primers and 5 ml QuantiTect
SYBR Green (Qiagen) in a final volume of 10 ml. Each run
included a positive control sample for amplification of the tbp gene
and negative controls for each primer pair in the presence or
absence of cDNA. The primers used for amplification of dr6 and
tbp were: 59-ATGACAACGCGACACACG-39 and 59-ATCCG-
GATGGAGTTCTAGGC-39 (dr6) and: 59-GCGGTTTGCTG-
CGGTAATCAT-39 and 59-GACTGTTCTTCACTCTTGGC-
TCCTGT-39 (tbp). The optimal condition was determined to be
an initial denaturing step at 95uC for 10 min, followed by 45 cycles
of 95uC for 15 s, 62uC for 20 s and 72uC for 15 s. Melting curves
were performed with one cycle at 95uC for 0 s, 72uC for 15 s, and
99uC for 0 s. The relative amount of mRNA for DR6 was
determined by the real-time PCR crossing point (Cp) and
normalized against the crossing point of tbp amplification using
the formula: 2
Cp(tbp) – Cp(DR6(6B)).
Generation of anti-DR6 polyclonal antibodies
Custom-made rabbit anti-DR6 polyclonal antibodies were
generated by Gencript, Piscataway, NJ, USA. In brief, rabbits
were immunized with a 14-amino acid peptide from the DR6 C-
terminal (Figure 1D) in order to generate a rabbit polyclonal anti-
DR6 antibody. The peptide was conjugated to a keyhole limpet
hemocyanin (KLH) carrier. Conjugated peptide (0.5 mg) and
complete Freund’s adjuvant was subcutaneously administered at
Figure 6. Complex formation of DR6(6B) and p41 during HHV-
6B infection. (A) Western blotting of input lysate before immunopre-
cipitation. Probed with anti-DR6. (B) Western blotting of p41 and
control IgG immunoprecipitation with or without HHV-6B-infection at
48 hpi. Probed with anti-DR6. (C) Western blotting of lysates after one
round of p41 and IgG immunoprecipitation. Blots were probed with
anti-DR6. A representative of two experiments is shown.
doi:10.1371/journal.pone.0007457.g006
DR6-p41 Complex Formation
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conjugated peptide and incomplete Freund’s adjuvant at day 14,
35, and 56 followed by a production bleed at day 70. The anti-
DR6 antibody was affinity purified and the purity was confirmed
by HPLC analysis. The specificity of the anti-DR6 antibody was
tested using an ELISA assay.
Cell lysis and Western blotting
HCT116 cells (2610
6) were either mock-treated or infected
with HHV-6B and lysed at 24, 48 or 72 hpi. Cells were lysed for
30 min in 16 lysis buffer (Cell Signaling, Technology Inc.,
Beverly, MA, USA) supplemented with 1 mM phenylmethanesul-
phonylfluoride (PMSF), 5 mM sodium fluoride (NaF) and
Complete Mini Protease Inhibitor (Roche Diagnostics) according
to the manufacturers recommendations. Lysates were centrifuged
at 4200 6g for 5 min, followed by a 10 min centrifugation at
20.000 6g to remove cell debris completely. Nuclear and
cytoplasmic extracts were prepared from T cells (nuclear extract
kit; Active Motif, Rixensart, Belgium) with and without HHV-6B
infection at 48 hpi as previously described [12]. Protein
concentrations of the lysates were measured by the Bradford
method and 30 mg protein of each lysate were separated on an XT
Criterion 10% gel (Bio-Rad, Copenhagen, Denmark) with 16XT
MOPS running buffer (Bio-Rad) for 1 hour at 175 V (constant)
and subsequently electro-transferred to a nitrocellulose membrane
at 300 mA (constant) for 1.5 hours.
The following antibodies were used for Western blotting: Rabbit
anti-DR6 antibody (1:1000); rabbit anti-GAPDH antibody (1:2000)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); mouse anti-p41
antibody (1:500) (Advanced Biotechnologies, Tebu-Bio, Columbia,
USA); mouse anti-7c7 antibody (1:600) (Argene Biosoft, Verniolle,
France); goat anti-RCC1 antibody (1:500) (Santa Cruz Biotechnol-
ogy); horseradish peroxidase-conjugated polyclonal swine anti-
rabbit antibody (P0217); horseradish peroxidase-conjugated poly-
clonal rabbit anti-mouse antibody (P0260); horseradish peroxidase-
conjugated polyclonal rabbit anti-goat (P0449) (all from Dako,
Glostrup, Denmark). All of the peroxidase-conjugated antibodies
wereused at 1:2000 dilution in 5%skimmedmilk inTBS with 0.1%
Tween 20 (Sigma-Aldrich). Membranes were developed with
Chemiluminescence pico or femto (Pierce, Thermo Scientific,
Slangerup, Denmark) and Image Reader Las-3000 (Science
Imaging Scandinavia AB, Sweden).
Confocal laser scanning microscopy
HCT116 cells were transferred to poly-L-lysine-coated slides
and incubated for 24 h. Cells were mock or HHV-6B infected and
incubated for additional 24, 48, or 72 h, followed by fixation in
4% formalin/PBS (pH 7.5). Cells were washed twice in PBS,
permeabilized in 0.2% Triton X-100 (Sigma-Aldrich)/PBS and
blocked in 5% BSA (Sigma-Aldrich)/PBS. DR6 was visualized
using rabbit anti-DR6 antibody (1:200) and p53 was visualized
with a rabbit anti-p53 antibody (1:200) (Santa Cruz Biotecnolo-
gies). TBP was visualized using mouse anti-TBP antibody (1:200)
(Abcam, Cambridge, UK) and p41 was visualized using mouse
anti-p41 antibody (1:500). The secondary antibodies were a goat
anti-rabbit F(ab’)2 antibody conjugated with Alexa Fluor 488
(Invitrogen) (1:400) and a goat anti-mouse F(ab’)2 antibody
conjugated with Alexa Fluor 546 (Invitrogen) (1:400). Nuclear
staining was performed with the DNA dye 49,6-diamidino-2-
phenylindole dihydrochloride (DAPI), (Sigma-Aldrich). Imaging
was done by using a 488 nm line of a multiline argon laser, the
543 nm line of the green helium–neon laser, and the 633 nm line
of the helium–neon laser on a confocal laser scanning microscope
(LSM710, Zeiss, Jena, Germany) with a x63 oil-immersion
objective with a numerical aperture of 1.4.
Co-immunoprecipitation
HCT116 cells (2610
6) were either mock-treated or infected
with HHV-6B and incubated for 72 h before cell lysis. Antibodies
were coupled to protein A Dynabeads (Invitrogen) using 5 mg
mouse anti-p41 antibody or control mouse-IgG2a (Sigma-Aldrich)
by rotating the mixture for 10 min at room temperature. Beads
were washed twice in PBS and the antibody-bead binding was
crosslinked with 5 mM subericacid bis (3-sulfo-N-hydroxysuccini-
mide ester) sodium salt (BS
3) (Sigma Aldrich) for 30 min at RT,
after which the crosslinking was quenched using 1 M TrisHCl
(pH 7,5). Finally the antibody-conjugated beads were incubated
with 400 mg of protein lysate for 10 min at 4uC, followed by 3
washing steps in PBS supplemented with 0.1% Tween 20 (Sigma-
Aldrich). Bound protein was eluted with 5 volumes of 4x sample
buffer (Bio-Rad) and 1 volume of reducing agent (Bio-Rad).
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